Related Experiment Video
Updated: May 8, 2025
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
Published on: February 23, 2024
Challenges in Implementing Comprehensive Precision Medicine Screening for Ovarian Cancer
Laura R Moffitt1,2, Nazanin Karimnia1,2, Amy L Wilson1,2
1Hudson Institute of Medical Research, Clayton 3168, Australia.
Abstract:
Precision medicine has revolutionised targeted cancer treatments; however, its implementation in ovarian cancer remains challenging. Diverse tumour biology and extensive heterogeneity in ovarian cancer can limit the translatability of genetic profiling and contribute to a lack of biomarkers of treatment response. This review addresses the barriers in precision medicine for ovarian cancer, including obtaining adequate and representative tissue samples for analysis, developing functional and standardised screening methods, and navigating data infrastructure and management. Ethical concerns related to patient consent, data privacy and health equity are also explored. We highlight the socio-economic complexities for precision medicine and propose strategies to overcome these challenges with an emphasis on accessibility and education amongst patients and health professionals and the development of regulatory frameworks to support clinical integration. Interdisciplinary collaboration is essential to drive progress in precision medicine to improve disease management and ovarian cancer patient outcomes.
Insights
Precision medicine offers targeted cancer treatments but faces challenges in ovarian cancer due to tumor diversity. Overcoming barriers like sample quality, standardized methods, and data management is crucial for improving patient outcomes.
Area of Science:
- Oncology
- Genomics
- Translational Medicine
Background:
- Precision medicine has transformed cancer care, yet its application in ovarian cancer is hindered by significant biological complexity.
- Ovarian cancer's diverse tumor biology and heterogeneity complicate genetic profiling and the identification of treatment response biomarkers.
Purpose of the Study:
- To review the multifaceted barriers impeding the implementation of precision medicine in ovarian cancer.
- To explore ethical, socio-economic, and logistical challenges associated with precision oncology in this disease.
Main Methods:
- Literature review and synthesis of current research on precision medicine in ovarian cancer.
- Analysis of challenges in tissue acquisition, assay development, data infrastructure, and ethical considerations.
Main Results:
- Key barriers include obtaining adequate tissue, standardizing screening assays, and managing complex data infrastructure.
- Ethical issues concerning patient consent, data privacy, and health equity require careful navigation.
Conclusions:
- Addressing socio-economic factors, enhancing patient and professional education, and developing supportive regulatory frameworks are vital.
- Interdisciplinary collaboration is essential for advancing precision medicine and improving ovarian cancer patient care and outcomes.
